Recent News

EMERGING-CTONG 1103 Trial: Neoadjuvant Erlotinib in EGFR-Mutant Lung Cancer

Entrectinib Approved by FDA for ROS1-Positive NSCLC

Two-Drug Combination Targets Resistance in Cancer

Early Results With Dual Inhibition of VEGFR2 and PD-1 in Advanced Lung Cancer

Can Lower Radiation Doses Reduce Damage to Immune System and Improve Outcomes in NSCLC?

Pemetrexed/Carboplatin/Gefitinib: New Standard of Care for Untreated EGFR-Mutant Lung Cancer?

A Risk Prediction Model For Patients With Lung Nodules

Adjuvant Therapy for Completely Resected Advanced Nonsquamous NSCLC

RET Inhibitor Shows Activity in Select Patients With Lung Cancer in ARROW Trial

FDA Approves Bevacizumab Biosimilar in Nonsquamous NSCLC

ASCO 2019: Dual EGFR and VEGFR Blockade in Metastatic Lung Cancer

ASCO 2019: Interim Results With Neoadjuvant Atezolizumab in Resectable Lung Cancer

ASCO 2019: Proton Therapy Versus Conventional Photon Therapy in Locally Advanced Cancer

ASCO 2019: Comparing Maintenance Therapies for Nonsquamous Lung Cancer

ASCO 2019: Neoadjuvant Combination Checkpoint Blockade in Early-Stage NSCLC

ASCO 2019: Long-Term Survival With Pembrolizumab for Advanced NSCLC

ASCO 2019: Expanding Traditional Clinical Trial Eligibility in NSCLC

Predicting the Course of Lung Cancer in Situ

Pooled Analysis of Use of Entrectinib in ROS1-Positive Lung Cancer

Lung Cancer Organizations Launch Collaborative Foundation for Lung Cancer Community

ELCC 2019: Does Age Affect Toxicity in Immunotherapy-Treated Patients With NSCLC?

ELCC 2019: Patient-Reported Outcomes With Durvalumab in NSCLC

Can Clinical Use of Capsaicin Slow the Spread of Lung Adenocarcinoma?

ELCC 2019: First-Line Treatment With Osimertinib in Advanced EGFR -Mutant NSCLC

ELCC 2019: Larotrectinib in TRK Fusion–Positive Lung Cancer

AACR 2019: Savolitinib Plus Osimertinib in EGFR -Mutant, MET-Amplified NSCLC

ELCC 2019: Pembrolizumab Monotherapy in Elderly Patients With Advanced NSCLC

HOPA 2019: Flat-Dose Nivolumab Dosing in First-Line Treatment of NSCLC

FDA Expands Pembrolizumab Indication in First-Line Treatment of NSCLC

Novel Approach to Predicting Adverse and Beneficial Effects of Immunologic Interventions

Role for Oxoglutarate Carrier in Formation of Lung Cancer

Less Frequent Dosing of Nivolumab in NSCLC

STS 2019: Identifying Candidates for Adjuvant Therapy for Early-Stage Lung Adenocarcinoma

STS 2019: Can Mutations Predict Survival After Pulmonary Metastasectomy for Colorectal Cancer?

Thoracic Cancers Symposium 2019: Evidence-Based Decision-Making in NSCLC

ASCO-SITC 2019: Predicting Response to Immunotherapy in NSCLC

Thoracic Cancers Symposium 2019: Local Consolidative Therapy for Oligometastatic NSCLC

AACR 2019: Clinical Utility of Cell-Free DNA Liquid Biopsy in Metastatic Lung Cancer

2019 ASCO-SITC Symposium: Neoadjuvant Atezolizumab in NSCLC

2019 ESMO TAT: Predicting Outcomes With Lung Immune Prognostic Index

2019 ASCO-SITC Symposium: Vaccine Plus Nivolumab in Lung Cancer

FDA Grants Priority Review for Entrectinib in ROS1-Positive NSCLC